Progress Forward

[Progress Forward @progressfwd96]

@unusual_whales I am sure the fact that they have raised prices by more than 100% since Covid is not part of the problem.

[Progress Forward @progressfwd96]

@ShardiB2 @nypost I like vacation Shardi!

[Progress Forward @progressfwd96]

@KanKanandB Your coverage of $BFLY has helped boost my long term conviction to hold the stock versus a short term swing. Have you looked into $ABCL?

[Progress Forward @progressfwd96]

@Liathetrader @TheCryptoCPA Not saying you are wrong Lia but I don’t think most feel entitled to assistance but to Sheehans point, if a parent has the ability to assist today, it will be a greater benefit to the person to gain that assistance today versus 40 years from today.

[Progress Forward @progressfwd96]

@Liathetrader @TheCryptoCPA Did your family have any wealth to share and would you have benefited from family assistance is a better question. Most in their 20s and 30s are not on Fintwit and are grinding 50+ hour weeks struggling due to inflation and can’t see past the hamster wheel they are stuck on.

[Spencer Pratt @spencerpratt]

God Bless America

[Progress Forward @progressfwd96]

@alessandrorisk @crypto_banter This was a great listen!

[Jack Prescott @JackPrescottX]

https://t.co/rnRV9hYIqM

[Alpha @AlAlphaResearch]

$ABCL AbCellera is one of those companies where the more you dig, the more interesting it gets. Most people still haven't connected all the pieces.

#AbCellera built a fully integrated antibody discovery platform that takes a drug from concept to clinical candidate faster than traditional pharma can. During COVID, they developed bamlanivimab in under 90 days. That speed isn't a one time thing. It's the platform. 203 active clinical programs. 14 molecules in clinical stage. All running on the same discovery engine.

The platform is now getting externally validated in a way that's hard to ignore.

June 17, Jazz Pharmaceuticals announced a multi-program TCE collaboration with AbCellera for next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and solid tumors. $56M in upfront payments. Up to $792M per program in option fees and milestones. Five programs total, potential value up to ~$4B. Plus tiered royalties on net sales ranging from mid-single to low double digits. Jazz has already committed to starting a third program within 12 months, before any data from the first two programs exists. That's not a company testing a relationship. That's a company building a pipeline inside someone else's platform.

This is also not AbCellera's first major TCE deal. AbbVie expanded their TCE collaboration in January 2025. Jazz just validated the same platform from a completely different angle in oncology.

Then there's ABCL635, their internal NK3R antibody for menopausal hot flashes. Phase 1 data in May showed zero liver toxicity across all doses from 30mg to 900mg. Half life of approximately 24 days supporting once monthly dosing. Target engagement confirmed. Phase 2 is already enrolling. Q3 topline efficacy data is the next catalyst.

For context, Veozah, the only approved oral NK3R drug, carries a Black Box Warning for liver toxicity and still generated $234M in its first nine months on market. ABCL635 showed zero liver enzyme elevations at doses more than 20 times higher than Veozah's approved dose. The dosing headroom Astellas never had is sitting right there.

The balance sheet is what makes all of this genuinely interesting as a risk reward. $655M in total liquidity. Current ratio of 14.05. Zero long term debt. The Jazz $56M upfront is non-dilutive cash that lands on top of that. For a clinical stage biotech, this is an unusually strong position to be in.

CEO Carl Hansen owns 20.9% of the company. Goldman accumulated 4.3M shares. Baker Bros increased from 9.1% to 10.8% the day before the Phase 1 readout. Simply Wall St fair value estimate $10.43 against a current price of $5.74, flagging 45% potential undervaluation.Two independent shots at value creation running simultaneously. ABCL635 Phase 2 in Q3. Jazz TCE platform deal generating near-term cash and long term royalty optionality. Neither depends on the other.

The market is still pricing this like a company with one drug in the pipeline. The actual story is a platform company that keeps getting paid to let large pharma use its engine, while also running its own most promising asset toward the most important data readout of the year.

[FDA Medical Devices @FDADeviceInfo]

The FDA’s AI stance in action!

The agency just cleared an AI ultrasound tool that estimates gestational age in under 2 minutes.

This is the model: support innovation that expands access and improves speed, while holding firm on safety and effectiveness.

[Progress Forward @progressfwd96]

@ShardiB2 Thanks to @ShardiB2 my $BFLY position is up 338% from entry on her call! Appreciate you!

[Fiboswanny @FiboSwanny]

more fibs to watch early in the life

[Ondo Finance @OndoFinance]

It is with profound sadness that we announce the unexpected passing of Nathan Allman, Ondo's founder. Our hearts are with his family and loved ones.

Nate’s brilliance, humility, and drive shaped every part of what Ondo is today. His belief in the power of technology to create a more open, accessible financial system lives on in everything we build. The impact he had on this industry, and on all of us personally, cannot be overstated.

Nate also helped us build a durable organization with experienced leaders across all facets of the business. Ian De Bode, Ondo Finance’s longtime President, will serve as CEO. Ian has been leading our strategy, product, and day-to-day operations for over two years and has the full confidence of the leadership team.

We will continue building what Nate started. That is the most meaningful way we know to honor him.

[Progress Forward @progressfwd96]

@scottmelker Probably your best tweet 😂

[Progress Forward @progressfwd96]

@ShardiB2 $KOID Is another robotics ETF you mentioned months ago that is up over 30% since you brought it up.

[Progress Forward @progressfwd96]

@Liathetrader $STRC and chill

[Progress Forward @progressfwd96]

@PolarizingLit I only found your account fairly recently and really appreciate your takes and transparency. Surprised you don’t have a larger following. I appreciate your content!